Chronic Myeloid Leukemia
Conditions
Brief summary
This study to find out more about how patients take their anticancer medications and challenges related to taking cancer medications.
Detailed description
120 patients with Chronic Myeloid Leukemia (CML) who are currently prescribed an oral anti-cancer agent from up to 6 CCDR NCORP sites to complete a brief interviewer administered survey to assess medication adherence and related factors.
Interventions
None listed
Sponsors
Wake Forest University Health Sciences
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is diagnosed with Chronic Myeloid Leukemia (CML) and is receiving care for CML at a participating CCDR NCORP practice, * Patient had been prescribed one of the following oral anticancer agents for CML for ≥30 days (Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib). Prior use of any of these medications is allowed, as long as they have been on a stable regimen for at least 30 days prior to enrollment. * Patient is 18 years of age or older
Exclusion criteria
* Patient does not speak English or requires an interpreter for medical visits * Patient is cognitively impaired, as determined by the referring provider
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Demographic and Health Behaviors Questionnaire | Study 1 day Visit | Questions will be asked about the participants demographic background and health behaviors. |
| Brief Medication Questionnaire (BMQ) | Study 1 day Visit | A self-report tool for screening adherence and barriers to adherence. The tool includes a 5-item Regimen Screen that asks patients how they took each medication in the past week, a 2-item Belief Screen that asks about drug effects and bothersome features, and a 2-item Recall Screen about potential difficulties remembering. |
| Single Item Adherence Measure 1 | Study 1 day Visit | This is a single question. This measure was developed to serve as simple means of identifying sub-optimal adherence which could help identify at-risk patients for interventions. |
| Single Item Adherence Measure 2 | Study 1 day Visit | This single item was developed to evaluate self-report adherence to medication and has demonstrated low patient burden and the ability to predict adherence-related clinical outcomes as good or better than other adherence measures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| REALM-SF | Study 1 day Visit | The REALM-SF offers researchers a simplified, validated, and efficient instrument for assessing patient literacy in clinical setting. It can be used to investigate the relationship between literacy and specific health outcomes such as medication adherence and health care utilization. |
| Medications Adherence Reasons Scale (MARS) | Study 1 day Visit | This questionnaire is designed to identify potential risk factors associated with medication-related non-adherence. |
Countries
United States
Outcome results
None listed